Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution
Nature – Convergent mutations in hotspots of the SARS-CoV-2 Omicron receptor-binding domain can cause immune evasion and maintain sufficient ACE2-binding capability.
Related Articles
2024 FDA approvals
Nature Reviews Drug Discovery – The FDA approved 50 new therapeutics in 2024, with green lights for a novel schizophrenia drug, a first NASH medicine…
Green steel, thunderstorms and next-generation gene editing: a year of remarkable science
Nature – Highlights from News & Views published in 2024
Lotte Bjerre Knudsen (@lotte_bjerre) on X
Passionate about human-centric science, applied science, GLP-1, Novo Nordisk, D&I, as well as food, Brunello, family and my one and only daughter Kitt
Lotte Bjerre Knudsen: The Scientist Who Drove GLP-1 Drugs For Obesity and Alzheimer’s
Facts, data, and analytics about biomedical matters.
2024 FDA approvals
Nature Reviews Drug Discovery – The FDA approved 50 new therapeutics in 2024, with green lights for a novel schizophrenia drug, a first NASH medicine…
Renal denervation for hypertension
Nature Reviews Cardiology – Endovascular renal denervation has been approved for the treatment of hypertension. In this Review, Fisher and Kirtane discuss the clinical trial…
Tattoo ink induces inflammation in the draining lymph node and impairs the immune response against a COVID-19 vaccine
Despite safety concerns regarding the toxicity of tattoo ink, no studies have reported the consequences of tattooing on the immune response. In this work, we…
Ultrasonic optic nerve sheath diameter as a new predictor for the mortality of patients with large hemispheric infarction
Scientific Reports – Ultrasonic optic nerve sheath diameter as a new predictor for the mortality of patients with large hemispheric infarction
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
Nature Medicine – In an ongoing phase 1 trial, the combination of two new immunotherapies targeting CTLA-4 and PD-1 was overall well tolerated and elicited…
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
Oncogene – Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer